Form 8-K

8-K — Lifevantage Corp

Accession: 0001193125-26-208934

Filed: 2026-05-06

Period: 2026-05-06

CIK: 0000849146

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — lfvn-20260506.htm (Primary)

EX-99.1 (lfvn-ex99_1.htm)

GRAPHIC (img3529843_0.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: lfvn-20260506.htm · Sequence: 1

8-K

0000849146falseLifevantage Corp00008491462026-05-062026-05-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 06, 2026

Lifevantage Corporation

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-35647

90-0224471

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

3300 N. Triumph Blvd, Suite 700

Lehi, Utah

84043

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (801) 432-9000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001

LFVN

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 6, 2026, the Company issued a press release announcing its financial results for the three and nine months ended March 31, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 to this report and incorporated by reference.

The information furnished in this Item 2.02 and the exhibit hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release issued by the Company on May 6, 2026, announcing its financial results for the three and nine months ended March 31, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LIFEVANTAGE CORPORATION

Date:

May 6, 2026

By:

/s/ Carl A. Aure

Name: Carl A. Aure

Title: Chief Financial Officer

EX-99.1

Filename: lfvn-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

LifeVantage Announces Financial Results for the

Third Quarter of Fiscal 2026

Salt Lake City, UT, May 6, 2026, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2026.

Third Quarter Fiscal 2026 Summary*:

•

Revenue was $43.7 million, a decrease of 25.2% from the prior year period;

•

Revenue in the Americas decreased 28.9%, and revenue in Asia/Pacific & Europe decreased 7.7%;

•

Net income per diluted share was $0.11, versus $0.26 per diluted share a year ago;

•

Adjusted earnings per diluted share was $0.12, compared to $0.26 a year ago; and

•

Adjusted EBITDA was $3.2 million compared to $6.4 million a year ago.

* All comparisons are on a year over year basis and compare the third quarter of fiscal 2026 to the third quarter of fiscal 2025, unless otherwise noted.

"Third quarter results were softer than we anticipated as lower sales of our MindBody GLP-1 SystemÒ were only partially offset by the addition of LoveBiome," said Michael Beindorff, Interim CEO of LifeVantage. "Despite top-line headwinds, we remained focused on managing expenses and allocating capital, enabling us to continue repurchasing shares while maintaining a strong balance sheet and cash position. That said, we are not satisfied with our performance and are laser focused on making the changes necessary to improve results going forward. With our science-backed approach to nutrigenomics, diversified product portfolio, passionate consultant community, and strong financial foundation, LifeVantage is in a compelling position in the rapidly expanding health and wellness market with significant growth potential ahead, and we intend to realize that potential."

Third Quarter Fiscal 2026 Results

For the third quarter ended March 31, 2026, the Company reported revenue of $43.7 million, a 25.2% decrease compared to revenue of $58.4 million in the third quarter of fiscal 2025. Revenue in the Americas region for the third quarter of fiscal 2026 decreased 28.9% primarily due to declines in sales of the MindBody GLP-1 SystemÒ, partially offset by sales of LoveBiome, which the Company acquired in October 2025. Revenue in the Asia/Pacific & Europe region decreased 7.7%; on a constant currency basis, revenue in the Asia/Pacific & Europe region decreased approximately 8.9%.

Gross profit for the third quarter of fiscal 2026 was $34.5 million, or 79.0% of revenue, compared to $47.3 million, or 81.0% of revenue, for the same period in fiscal 2025. The decrease in gross profit as a percentage of revenue was primarily due to an allowance for inventory obsolescence related to the MindBody GLP-1 SystemÒ, along with increases in shipping and warehouse related expenses. Adjusted for the allowance for inventory obsolescence, non-GAAP gross profit was $34.7 million, or 79.4% of revenue.

Commissions and incentives expense for the third quarter of fiscal 2026 was $19.0 million, or 43.5% of revenue, compared to $26.2 million, or 44.8% of revenue, for the same period in fiscal 2025. The decrease in commissions and incentives expenses as a percentage of revenue compared to the prior year period is primarily due to the timing

and magnitude of promotional and incentive programs and changes to the mix of customers and independent consultants in our overall Active Accounts.

Selling, general and administrative (SG&A) expense for the third quarter of fiscal 2026 was $13.9 million, or 31.7% of revenue, compared to $17.1 million, or 29.2% of revenue, for the same period in fiscal 2025. The increase in SG&A expenses as a percentage of revenue was primarily due to the overall decrease in sales volume.

Operating income for the third quarter of fiscal 2026 was $1.7 million compared to $4.1 million for the third quarter of fiscal 2025. Adjusted non-GAAP operating income for the third quarter of fiscal 2026 was $1.8 million compared to adjusted non-GAAP operating income of $4.1 million for the third quarter of fiscal 2025.

Net income for the third quarter of fiscal 2026 was $1.4 million, or $0.11 per diluted share, compared to $3.5 million, or $0.26 per diluted share for the third quarter of fiscal 2025. Adjusted non-GAAP net income for the third quarter of fiscal 2026 was $1.5 million, or $0.12 per diluted share, compared to adjusted non-GAAP income of $3.5 million, or $0.26 per diluted share, for the third quarter of fiscal 2025.

Adjusted EBITDA was $3.2 million for the third quarter of fiscal 2026, versus $6.4 million for the comparable period in fiscal 2025.

Balance Sheet & Liquidity

The Company generated $5.5 million of cash from operations during the first nine months of fiscal 2026 compared to $10.8 million in the same period in fiscal 2025. The Company's cash and cash equivalents at March 31, 2026 were $12.5 million, compared to $20.2 million at June 30, 2025, and there was no debt outstanding.

Share Repurchase

During the first nine months of fiscal 2026, the Company repurchased approximately 250,000 of its common shares for an aggregate price of approximately $1.6 million. As of March 31st, there was $59.0 million remaining under the $60 million share repurchase program approved by the Company’s Board of Directors in January.

Dividend Announcement

Today the Company announced the declaration of a cash dividend of $0.05 per common share, an 11.1% increase from the previous quarterly dividend of $0.045 per common share. The dividend will be paid on June 15, 2026 to all stockholders of record at the close of business on June 1, 2026.

Fiscal Year 2026 Guidance

The Company anticipates fiscal 2026 revenue, adjusted EBITDA, and adjusted earnings per share to be close to the lower end of our previously issued guidance range. The Company expects a full year tax rate of approximately 18% to 20%. This guidance reflects the current trends in the business and the Company's strategic initiatives, including international expansion and new product launches. The Company's guidance for adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per diluted share excludes any non-operating or non-recurring expenses that may materialize during fiscal 2026.

Conference Call Information

The Company will hold an investor conference call today at 2:30 p.m. MST (4:30 p.m. EST). Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after the call concludes and will be available through Wednesday, May 20, 2026, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13759699, or (412) 317-6671 from international locations, and entering confirmation code 13759699.

There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://lifevantage.gcs-web.com/events-and-presentations. The webcast will be archived for approximately 30 days.

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the MindBody GLP-1 SystemÒ, the newest comprehensive gut activator from LoveBiome P84, the Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic and hydration energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

Cautionary Note Regarding Forward Looking Statements

This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison both to past dividends and to current expectations. Examples of forward-looking statements include, but are not limited to, expected financial performance, including revenue margins, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, and expected dividend payments in future quarters. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission (the “SEC”). The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

About Non-GAAP Financial Measures

We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding.

We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.

The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.

Investor Relations Contacts:

Reed Anderson, ICR

(646) 277-1260

reed.anderson@icrinc.com

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)

March 31, 2026

June 30, 2025

(In thousands, except per share data)

ASSETS

Current assets

Cash and cash equivalents

12,483

20,201

Accounts receivable

2,420

3,294

Income tax receivable

2,200

635

Inventory, net

18,382

20,669

Prepaid expenses and other

3,829

6,095

Total current assets

39,314

50,894

Property and equipment, net

6,850

6,207

Right-of-use assets

6,908

8,041

Intangible assets, net

3,187

245

Goodwill

472

—

Deferred income tax asset

4,805

5,970

Other long-term assets

591

601

TOTAL ASSETS

62,127

71,958

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities

Accounts payable

5,147

4,600

Commissions payable

5,948

7,237

Lease liabilities

1,885

1,867

Other accrued expenses

7,121

13,513

Total current liabilities

20,101

27,217

Long-term lease liabilities

8,321

9,811

Other long-term liabilities

366

289

Total liabilities

28,788

37,317

Commitments and contingencies

Stockholders’ equity

Preferred stock — par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding

—

Common stock — par value $0.0001 per share, 40,000 shares authorized and 12,609 and 12,429 issued and outstanding as of March 31, 2026 and June 30, 2025, respectively

Additional paid-in capital

138,726

139,962

Accumulated deficit

(103,656

)

(104,147

)

Accumulated other comprehensive loss

(1,732

)

(1,175

)

Total stockholders’ equity

33,339

34,641

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

62,127

71,958

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended

March 31,

Nine Months Ended

March 31,

2026

2025

2026

2025

(In thousands, except per share data)

Revenue, net

43,716

58,440

140,209

173,416

Cost of sales

9,172

11,113

31,639

33,799

Gross profit

34,544

47,327

108,570

139,617

Operating expenses:

Commissions and incentives

19,001

26,208

59,591

79,038

Selling, general and administrative

13,865

17,066

44,546

50,528

Total operating expenses

32,866

43,274

104,137

129,566

Operating income

1,678

4,053

4,433

10,051

Other income (expense):

Interest income, net

131

320

Other expense, net

(46

)

(194

)

(524

)

Total other income (expense)

(22

)

127

(63

)

(204

)

Income before income taxes

1,656

4,180

4,370

9,847

Income tax expense

(294

)

(710

)

(577

)

(2,001

)

Net income

1,362

3,470

3,793

7,846

Net income per share:

Basic

0.11

0.28

0.30

0.64

Diluted

0.11

0.26

0.30

0.60

Weighted-average shares outstanding:

Basic

12,625

12,350

12,555

12,227

Diluted

12,660

13,300

12,757

12,985

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

Revenue by Region

(Unaudited)

Three Months Ended March 31,

Nine Months Ended March 31,

2026

2025

2026

2025

Americas

34,268

78.4

48,201

82.5

110,006

78.5

142,246

82.0

Asia/Pacific & Europe

9,448

21.6

10,239

17.5

30,203

21.5

31,170

18.0

Total

43,716

100.0

58,440

100.0

140,209

100.0

173,416

100.0

Active Accounts

(Unaudited)

As of March 31,

Change

from Prior

Percent

2026

2025

Year

Change

Active Independent Consultants

Americas

30,000

66.7

35,000

67.3

(5,000

)

(14.3

Asia/Pacific & Europe

15,000

33.3

17,000

32.7

(2,000

)

(11.8

Total Active Independent Consultants

45,000

100.0

52,000

100.0

(7,000

)

(13.5

Active Customers

Americas

51,000

79.7

74,000

84.1

(23,000

)

(31.1

Asia/Pacific & Europe

13,000

20.3

14,000

15.9

(1,000

)

(7.1

Total Active Customers

64,000

100.0

88,000

100.0

(24,000

)

(27.3

Active Accounts

Americas

81,000

74.3

109,000

77.9

(28,000

)

(25.7

Asia/Pacific & Europe

28,000

25.7

31,000

22.1

(3,000

)

(9.7

Total Active Accounts

109,000

100.0

140,000

100.0

(31,000

)

(22.1

(1) Active Independent Consultants have purchased product in the prior three months for retail or personal consumption.

(2) Active Customers have purchased product in the prior three months for personal consumption only.

(3) Total Active Accounts is the sum of Active Independent Consultant accounts and Active Customer accounts.

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA

(Unaudited)

Three Months Ended

March 31,

Nine Months Ended

March 31,

2026

2025

2026

2025

(In thousands)

GAAP Net Income

1,362

3,470

3,793

7,846

Interest income, net

(24

)

(131

)

(131

)

(320

)

Provision for income taxes

294

710

577

2,001

Depreciation and amortization

714

802

2,076

2,406

Non-GAAP EBITDA

2,346

4,851

6,315

11,933

Adjustments:

Stock compensation expense

704

1,522

2,083

4,160

Other expense, net

194

524

Other adjustments(1)

2,390

713

Total adjustments

835

1,577

4,667

5,397

Non-GAAP Adjusted EBITDA

3,181

6,428

10,982

17,330

(1) Other adjustments breakout:

MB System allowance for inventory obsolescence

183

—

2,551

—

LoveBiome acquisition costs

—

201

—

Change in fair value of earnout

(100

)

—

(400

)

—

Key management severance expenses

—

188

Executive team recruiting and transition expenses

—

525

Other nonrecurring expenses, net of credits

—

Total adjustments

2,390

713

LIFEVANTAGE CORPORATION AND SUBSIDIARIES

Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS

(Unaudited)

Three Months Ended

March 31,

Nine Months Ended

March 31,

2026

2025

2026

2025

(In thousands, except per share data)

GAAP Net Income

1,362

3,470

3,793

7,846

Adjustments:

MB System allowance for inventory obsolescence

183

—

2,551

—

LoveBiome acquisition costs

—

201

—

Change in fair value of earnout

(100

)

—

(400

)

—

Key management severance expenses

—

188

Executive team recruiting and transition expenses

—

525

Other nonrecurring expenses, net of credits

—

Tax impact of adjustments(1)

100

(11

)

(430

)

(164

)

Total adjustments, net of tax

185

1,960

549

Non-GAAP Net income:

1,547

3,510

5,753

8,395

March 31, 2026

June 30, 2025

2026

2025

2026

2025

Diluted earnings per share, as reported

0.11

0.26

0.30

0.60

Total adjustments, net of tax

0.01

0.00

0.15

0.04

Diluted earnings per share, as adjusted(2)

0.12

0.26

0.45

0.65

(1) Tax impact is based on the estimated annual tax rate for the years ended June 30, 2026 and 2025, respectively.

(2) May not add due to rounding.

Reconciliation of GAAP Gross Profit to Non-GAAP Gross Profit

(Unaudited)

Three Months Ended

March 31,

Nine Months Ended

March 31,

2026

2025

2026

2025

(In thousands, except percentage data)

Revenue, net

43,716

58,440

140,209

173,416

Cost of sales

9,172

11,113

31,639

33,799

GAAP Gross profit

34,544

47,327

108,570

139,617

GAAP Gross profit percentage

79.0

81.0

77.4

80.5

Adjustments:

MindBody GLP-1 System™ allowance for inventory obsolescence

183

—

2,551

—

GAAP Gross profit

34,727

47,327

111,121

139,617

GAAP Gross profit percentage

79.4

81.0

79.3

80.5

GRAPHIC

Filename: img3529843_0.jpg · Sequence: 3

Binary file (6462 bytes)

Download img3529843_0.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Document And Entity Information

May 06, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 06, 2026

Entity Registrant Name

Lifevantage Corp

Entity Central Index Key

0000849146

Entity Emerging Growth Company

false

Entity File Number

001-35647

Entity Incorporation, State or Country Code

Entity Tax Identification Number

90-0224471

Entity Address, Address Line One

3300 N. Triumph Blvd, Suite 700

Entity Address, City or Town

Lehi

Entity Address, State or Province

Entity Address, Postal Zip Code

84043

City Area Code

(801)

Local Phone Number

432-9000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001

Trading Symbol

LFVN

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration